The Prototypic Antidepressant Drug, Imipramine, but not Hypericum perforatum (St. John's Wort), Reduces HPA-Axis Function in the Rat

Hormone and Metabolic Research

Volumn 35, Issue 10, 2003, Pages 602-606

  Frost, P ^a   Bornstein, S ^b   Ehrhart Bornstein, M ^b   O'Kirwan, F ^a   Hutson, C ^a   Heber, D ^c   Go, V ^c   Licinio, J ^a   Wong, M L ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE   (United States)

Author keywords

ACTH; Corticosterone; Major depressive disorder; Stress

Indexed keywords

ANTIDEPRESSANT AGENT; CORTICOSTERONE; CORTICOTROPIN; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE;

ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; HYPERICUM PERFORATUM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN;

ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CORTICOSTERONE; HYPERICUM; HYPOTHALAMUS; IMIPRAMINE; MALE; PITUITARY GLAND; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; HYPERICUM; HYPERICUM PERFORATUM;

EID: 0344155121     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-43507     Document Type: Article

References (25)

1. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50: 85-94
2. Keith SJ, Matthews SM. The value of psychiatric treatment: its efficacy in severe mental disorders. Psychopharmacol Bull 1993; 29: 427-430
3. Moller HJ, Volz HP. Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. Drugs 1996; 52: 625-638
4. Broekkamp CL, Leysen D, Peeters BW, Pinder RM. Prospects for improved antidepressants. J Med Chem 1995; 38: 4615-4633
5. Bilia AR, Gallon S, Vincieri FF. St. John's wort and depression. Efficacy, safety and tolerability-an update. Life Sci 2002; 70: 3077-3096
6. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression - an overview and meta-analysis of randomised clinical trials [see comments]. Bmj 1996; 313: 253-258
7. Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int Clin Psychopharmacol 2001; 16: 239-252
8. Muller WE, Rolli M, Schafer C, Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997; 2: 102-107
9. Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998; 1: 16-21
10. Neary JT, Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res 1999; 816: 358-363
11. Wirz A, Simmen U, Heilmann J, Calis I, Meier B, Sticher O. Bisanthraquinone glycosides of Hypericum perforatum with binding inhibition to CRH-1 receptors. Phytochemistry 2000; 55: 941-947
12. Butterweck V, Winterhoff H, Herkenham M. St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol Psychiatry 2001; 6: 547-564
13. Butterweck V, Korte B, Winterhoff H. Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacopsychiatry 34 Suppl 2001; 1: S2-7
14. Franklin M, Chi JD, Mannel M, Cowen PJ. Acute effects of LI 160 (extract of Hypericum perforatum, St John's wort) and two of its constituents on neuroendocrine responses in the rat. J Psychopharmacol 2000; 14: 360-363
15. Franklin M, Cowen PJ. Researching the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man. Pharmacopsychiatry 34 Suppl 2001; 1: S29-37
16. Brady LS, Whitfield HJ, Jr., Fox RJ, Gold PW, Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991; 87: 831-837
17. Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ, Jr.. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin- releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992; 572: 117-125
18. Wong ML, Khatri P, Licinio J, Esposito A, Gold PW. Identification of hypothalamic transcripts upregulated by antidepressants. Biochem Biophys Res Commun 1996; 229: 275-279
19. Kasper S. Hypericum perforatum - a review of clinical studies. Pharmacopsychiatry 34 Suppl 2001; 1: S51-55
20. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7: 541-547
21. Kaehler ST, Sinner C, Chatterjee SS, Philippu A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus [In Process Citation]. Neurosci Lett 1999; 262: 199-202
22. Gold PW. Stress-responsive neuromodulators. Biol Psychiatry 1988; 24: 371-374
23. Inder WJ, Prickett TC, Mulder RT, Donald RA, Joyce PR. Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology (Berl) 2001; 156: 73-78
24. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Muller WE. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 1998; 63: 499-510
25. Butterweck V, Wall A, Liefländer-Wulf U, Winterhoff H, Nahrstedt A. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry 30 Suppl 1997; 2: 117-124